Historical Valuation
Bright Minds Biosciences Inc (DRUG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.78. The fair price of Bright Minds Biosciences Inc (DRUG) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：90.01
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Bright Minds Biosciences Inc (DRUG) has a current Price-to-Book (P/B) ratio of 10.67. Compared to its 3-year average P/B ratio of 10.49 , the current P/B ratio is approximately 1.70% higher. Relative to its 5-year average P/B ratio of 7.40, the current P/B ratio is about 44.19% higher. Bright Minds Biosciences Inc (DRUG) has a Forward Free Cash Flow (FCF) yield of approximately -0.96%. Compared to its 3-year average FCF yield of -26.73%, the current FCF yield is approximately -96.39% lower. Relative to its 5-year average FCF yield of -31.83% , the current FCF yield is about -96.97% lower.
P/B
Median3y
10.49
Median5y
7.40
FCF Yield
Median3y
-26.73
Median5y
-31.83
Competitors Valuation Multiple
AI Analysis for DRUG
The average P/S ratio for DRUG competitors is 18521.22, providing a benchmark for relative valuation. Bright Minds Biosciences Inc Corp (DRUG.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for DRUG
1Y
3Y
5Y
Market capitalization of DRUG increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of DRUG in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is DRUG currently overvalued or undervalued?
Bright Minds Biosciences Inc (DRUG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.78. The fair price of Bright Minds Biosciences Inc (DRUG) is between to according to relative valuation methord.
What is Bright Minds Biosciences Inc (DRUG) fair value?
DRUG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Bright Minds Biosciences Inc (DRUG) is between to according to relative valuation methord.
How does DRUG's valuation metrics compare to the industry average?
The average P/S ratio for DRUG's competitors is 18521.22, providing a benchmark for relative valuation. Bright Minds Biosciences Inc Corp (DRUG) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Bright Minds Biosciences Inc (DRUG) as of Jan 09 2026?
As of Jan 09 2026, Bright Minds Biosciences Inc (DRUG) has a P/B ratio of 10.67. This indicates that the market values DRUG at 10.67 times its book value.
What is the current FCF Yield for Bright Minds Biosciences Inc (DRUG) as of Jan 09 2026?
As of Jan 09 2026, Bright Minds Biosciences Inc (DRUG) has a FCF Yield of -0.96%. This means that for every dollar of Bright Minds Biosciences Inc’s market capitalization, the company generates -0.96 cents in free cash flow.
What is the current Forward P/E ratio for Bright Minds Biosciences Inc (DRUG) as of Jan 09 2026?
As of Jan 09 2026, Bright Minds Biosciences Inc (DRUG) has a Forward P/E ratio of -17.40. This means the market is willing to pay $-17.40 for every dollar of Bright Minds Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Bright Minds Biosciences Inc (DRUG) as of Jan 09 2026?
As of Jan 09 2026, Bright Minds Biosciences Inc (DRUG) has a Forward P/S ratio of 0.00. This means the market is valuing DRUG at $0.00 for every dollar of expected revenue over the next 12 months.